ESMO 2012 - Roche conference call for investors and analysts Webcast Replay Download mp3 Presentation slides Investor Updates Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer Roche conference call for investors and analysts from ESMO 2012